Estrogens and selective estrogen receptor modulators in acromegaly

@article{Duarte2016EstrogensAS,
  title={Estrogens and selective estrogen receptor modulators in acromegaly},
  author={F. Duarte and R. Jallad and M. Bronstein},
  journal={Endocrine},
  year={2016},
  volume={54},
  pages={306-314}
}
Despite recent advances in acromegaly treatment by surgery, drugs, and radiotherapy, hormonal control is still not achieved by some patients. The impairment of IGF-1 generation by estrogens in growth hormone deficient patients is well known. Patients on oral estrogens need higher growth hormone doses in order to achieve normal IGF-1 values. In the past, estrogens were one of the first drugs used to treat acromegaly. Nevertheless, due to the high doses used and the obvious side effects in male… Expand
The significance of estrogen receptors in acromegaly: Are they useful as predictors of prognosis and therapy regimen?
  • Selma Ozturk, H. Donmez-Altuntas, +4 authors F. Bayram
  • Medicine
  • Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
  • 2020
TLDR
The results indicated that the high ESR1 and ESR2 gene expressions in acromegaly patients are associated to the decrease of pre-operative IGF-1 values and an inverse association was found between the pre-operatively insulin-like growth factor-1 (IGF-1) levels and the expressions of ESR 1/ESR2 gene in acRomegaly Patients. Expand
Preoperative treatment of growth hormone (GH) producing macroadenomas with somatostatin receptor ligands (SRLs) to improve surgical outcome: a critical analysis
TLDR
While all prospective studies suggested better surgical outcome for SRL-pretreated tumors 3 months post surgery, the differences in outcomes between pretreated and untreated control patients disappeared after 6–12 months and preoperative treatment of macrosomatotropinomas with SRLs should not be relied upon as a means to achieve complete tumor removal. Expand
Age- and Sex-Specific Differences as Predictors of Surgical Remission Among Patients With Acromegaly
TLDR
Premenopausal women with acromegaly tend to have larger tumors, more aggressive tumor types, and lower remission rates than do men, and further studies on the clinical implications are needed. Expand
Silent somatotroph pituitary adenomas: an update
TLDR
Silent growth hormone adenomas (SGHA) are a rare entity of non-functioning pituitary neuroendocrine tumors that are often uncovered by investigation for headaches or oligoamenorrhea. Expand
Effects of anti-estrogens on cell invasion and survival in pituitary adenoma cells: A systematic study
TLDR
Treatment of cells with SERMs caused cell apoptosis, as demonstrated by Caspase 3/7 activity and western blot assays, and the general applicability of SERMs for pituitary adenoma cells might be promising in clinical applications for the treatment of pituitARY adenomas. Expand
Pituitary Diseases and Bone
TLDR
Treatment of pituitary hormone excess and deficiency generally improves skeletal health, although some patients remain at high risk of fractures, and treatment with bone-active drugs may become mandatory. Expand
Management of hypopituitarism: a perspective from the Brazilian Society of Endocrinology and Metabolism.
TLDR
The different etiologies of hypopituitarism are discussed and one by one the clinical aspects, diagnostic evaluation, and therapeutic options for deficiencies of TSH, ACTH, gonadotropin, and GH are addressed. Expand
Gender differences and temporal trends over two decades in acromegaly: a single center study in 112 patients
TLDR
Gender-specific characteristics and an evolving spectrum of clinical presentation with implications for earlier diagnosis and personalized management of acromegaly are demonstrated. Expand
Acromegaly: Current Challenges and Future Directions in Latin America
Acromegaly is a rare disease, associated with significant morbidity and high mortality. The international literature provides different figures on the epidemiology of acromegaly in differentExpand
Influence of clomiphene citrate on induced ovarian hyperstimulation and subsequent fertility in Damascus goats
TLDR
Efficiency of substituting conventional gonadotropin-based superovulation with a clomiphene-based regimen in goats was investigated, and does that exhibited estrus were naturally mated soon after GnRH treatment and 24 h later. Expand
...
1
2
...

References

SHOWING 1-10 OF 84 REFERENCES
Estrogen treatment for acromegaly
TLDR
Adding estrogen treatment to their ongoing medical treatment, suppressed IGF-1 significantly in all patients, achieving hormonal remission in three of them, and could be an alternative, inexpensive adjuvant treatment for females with active acromegaly. Expand
Tamoxifen as a therapeutic agent in acromegaly
TLDR
Tamoxifen might be useful in the treatment of patients with biochemically-mild active acromegaly, but longer term studies are warranted. Expand
Clomiphene citrate for treatment of acromegaly not controlled by conventional therapies.
TLDR
Addition of CC should be considered an option in male acromegaly patients not controlled by current available options, with a considerable cost-saving benefit, and improvement of T levels can be obtained in those patients with concurrent central hypogonadism. Expand
Raloxifene decreases serum IGF-I in male patients with active acromegaly.
TLDR
Raloxifene might be useful in the treatment of male patients with active acromegaly, but longer term studies are clearly needed. Expand
Raloxifene lowers IGF-I levels in acromegalic women.
TLDR
RAL decreases IGF-I levels in most acromegalic women with mild or intermediate disease and normalizes it in many and a prospective randomized study in patients resistant or partially sensitive to other medical treatments is warranted. Expand
Estrogen and selective estrogen receptor modulators (SERMs) for the treatment of acromegaly: a meta-analysis of published observational studies
TLDR
It was concluded that estrogen and SERMs are a low cost and effective treatment to achieve control of IGF-1 levels in acromegalic women either as concomitant treatment for refractory disease, or where access to conventional therapy is restricted. Expand
Effects of tamoxifen on GH and IGF-I levels in acromegaly
TLDR
Tamoxifen (TAM), a non steroid partially competitive antagonist to the estrogen receptors, has been reported to decrease plasma GH and IGF-I levels both in vitro and in vivo, and it is likely that the observed decrease in plasma IGF- I levels is dependent on TAM activity at the hepatic level. Expand
Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels.
TLDR
The high remission rate reported, the absence of overlapping side effects between tamoxifen and somatuline and the synergistic activity on IGF-I suppression justify a further evaluation of the drug-combination. Expand
Tamoxifen enhances the control of acromegaly treated with somatostatin analog lanreotide
TLDR
The case of a 51-year old female patient with acromegaly that was resistant to somatostatin analogs and dopamine agonists and diagnosed with breast cancer requiring treatment with the anti-estrogen tamoxifen is presented. Expand
Tamoxifen reduces serum insulin-like growth factor I (IGF-I)
TLDR
Recent clinical and laboratory data suggest that the commonly used antiestrogen tamoxifen also acts to reduce serum IGF-I levels, which may contribute to the cytostatic activity of the drug. Expand
...
1
2
3
4
5
...